America's Medicine Cabinet Runs Through China as Trump Heads Into Xi Summit

When President Trump meets Chinese leader Xi Jinping at the Asia-Pacific Economic Cooperation gathering in Shenzhen next week, it will be the third sit-down between the two men, held under a fragile trade truce, according to Bloomberg ^[6]. The run-up has been clouded by reports that a Chinese businesswoman who had a relationship with Nvidia chief executive Jensen Huang was passing intelligence to Beijing. China's foreign ministry pushed back, saying, "The so-called Chinese spy allegation is unsubstantiated." ^[6]

Chips and espionage will grab the headlines. But a quieter vulnerability sits in nearly every American medicine cabinet. Economist Milton Ezrati, writing in The Epoch Times, argues that China's hold on the drug supply could become a pressure point much like its control of rare-earth minerals ^[1]. He notes that Beijing has not openly used that leverage, likely out of humanitarian concern, but that the medical supply shortfalls of the COVID-19 pandemic showed how much the world leans on Chinese sources ^[1].

How Deep the Dependence Runs

The numbers behind that warning are sobering. A June 2026 report from the Council on Foreign Relations found that China supplies the raw or key starting materials for about 94% of U.S. amoxicillin, 74% of heparin and 70% of acetaminophen ^[2]. About 41% of the key starting materials used in U.S.-approved active pharmaceutical ingredients come solely from China, and another 16% come from India, the report said ^[2]. The authors also cited a U.S. Pharmacopeia estimate that nearly 700 approved medicines depend on at least one chemical made only in China ^[2].

Ezrati adds that one-fourth of imported medicinal inputs come from product lines in which China supplies at least 75% of U.S. imports, and that for one in ten critical pharmaceutical inputs, China accounts for more than 99% of U.S. imports ^[1].

The trend is moving the wrong way. Data from the U.S. Pharmacopeia's Medicine Supply Map, reported by Becker's Hospital Review, show that China and India together accounted for 90% of new drug master files for active ingredients submitted for U.S. medicines in 2025 ^[3]. China's share of all active ingredient filings tied to U.S. medicines rose to 21%, up from 13% in 2021, while the American share slipped to 6% from 10% over the same stretch ^[3]. The United States accounted for just 3% of new filings ^[3]. USP called the concentration "a structural vulnerability within the U.S. pharmaceutical supply chain." ^[3] The White House put it even more plainly in 2025: "Only about 10% of APIs for U.S. prescription drugs are manufactured domestically." ^[4]

The India Problem

Many Americans assume drugs made in India offer a safe alternative. India is in fact the largest foreign supplier of generic medicines to the United States, and roughly 80% of the active ingredients used in this country come from China and India combined, according to the American Journal of Managed Care ^[5]. USP data show India holds 49% of active ingredient filings tied to U.S. medicines, the largest single share ^[3].

But India's factories lean on Chinese chemistry. Ezrati writes that India depends on China for 70% of its active ingredients and 90% of its critical antibiotics ^[1]. The CFR report found that India holds about 59% of amoxicillin finished-dose manufacturing but gets its intermediates from China, and that Indian manufacturers such as Dr. Reddy's source heparin ingredients entirely from China ^[2]. The report warned that Beijing could restrict those inputs to India and trigger shortages here, and that some Indian shipments reach U.S. ports through Mexico and Sri Lanka, which hides where they came from ^[2].

What It Means at the Kitchen Table

For families, this is not an abstract trade dispute. Generic drugs fill about 90% of U.S. prescriptions ^[5]. American doctors write more than 60 million amoxicillin prescriptions a year, the CFR report noted, yet the share of that antibiotic made by U.S. producers fell from 100% in 2008 to zero within twelve years under subsidized competition from China and India ^[2]. The 2022 amoxicillin shortage coincided with a 30.8% drop in amoxicillin prescriptions at U.S. pediatric hospitals ^[2].

Related Study Links Cannabis Use Disorder in Pregnancy to Higher Risk of Postpartum Psychiatric ER Visits

Heparin, the blood thinner given to more than 12 million hospitalized Americans each year, is another pressure point; Chinese manufacturers supply about 80% of the global supply and 74% of the U.S. supply ^[2]. And once shortages start, they linger. The CFR authors found that drug shortages now last about three years on average, up from two years in 2020 ^[2].

Scripture calls believers to care for the sick and the least of these. A nation that cannot make its own children's antibiotics has handed a rival a say over that care, and that should trouble Americans of every political stripe.

How Beijing Built Its Lead

China's position did not happen by chance. "China's commanding position is far from accidental," Ezrati writes ^[1]. He points to heavy subsidies for drug producers and easy credit from state-owned banks, which let Chinese firms undercut competitors around the world ^[1]. Beijing has also drawn clinical trials by making them faster, cheaper and less legally complicated than in the United States ^[1]. The CFR report found that China's share of first-in-human drug trial starts worldwide jumped from 1% in 2009 to 30% in 2024 ^[2].

The CFR authors were blunt about the risk: "China has both the tools and demonstrated willingness to weaponize U.S. pharmaceutical dependence." ^[2]

Washington's Response

The Trump administration has moved on two fronts: stockpiles and tariffs. In August 2025, the president signed an executive order directing the Department of Health and Human Services' preparedness office to compile a list of about 26 critical drugs and to stock a six-month supply of their active ingredients in the Strategic Active Pharmaceutical Ingredients Reserve, with a preference for American-made ingredients ^[4]. The order also called for updating a 2022 list of 86 essential medicines, planning a six-month ingredient supply for those drugs, and proposing a second storage site ^[4]. Trump first created the reserve in 2020 ^[4].

The CFR report noted that the reserve's purchasing rules rest on executive action that can be reversed or on discretionary funding, and it urged Congress to pay for an 18-month supply of critical ingredients ^[2].

On trade, Trump announced in July a phased plan for imported generic drugs: no tariff for two years starting Aug. 1, 2026, then 100% for one year, then 200% after that ^[5]. He described the eventual duty as "a penalty" for companies that fail to build manufacturing capacity in the United States in time ^[5]. A separate policy for patented brand-name drugs, with tariffs that can reach 100%, remains unchanged ^[5].

The generic drug industry has pushed back. The Association for Accessible Medicines said it wants more details and urged the administration to address existing barriers to building plants here; its leaders earlier warned that tariffs would not improve patient care ^[5]. The CFR authors favor tariffs aimed at products containing Chinese-sourced starting materials and ingredients rather than blanket duties on generics ^[2]. They also set goals of at least 25% non-Chinese sourcing of starting materials for essential medicines in the medium term, and allied or domestic production covering at least half of normal U.S. demand for priority drugs within a decade ^[2].

What Comes Next

The tariff clock is ticking toward 2028, though AJMC reported that the administration has not yet issued implementation guidance or said whether product-specific exemptions will be offered ^[5]. Ezrati points to other ideas, including biofermentation, price premiums for domestic producers and regulatory changes, but says none has yet reached Congress's agenda ^[1].

In Shenzhen, the president will be bargaining with the government that sits astride many of these supply lines. Whatever becomes of the trade truce, the lesson of the pandemic still stands: a country that wants to protect its families has to be able to make the medicines that keep them well.